Armstrong CP, Blower Al. 1997. Non-steroidal anti-inﬂammatory drugs and life threatening of peptic ulceration. Gut, 28:527–32. Bardan KD, Muller-Lissner S, Bigard A, et al. 1999. Symptomatic gastro- oesophagel reﬂux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ, 318:502–7. Bardhan KD, Bishop AE, Polak JM, et al. 2005. Pantoprazole in severe acid peptic disease: the effectiveness and safety of 5 years’ continuous treatment. Dig Liv Dis, 37:10–22. Berardi RR. 2006. A critical evaluation of proton pump inhibitors in the treatment of esophageal reﬂux disease. Am J Managed Care, 6(9 suppl):S491–S503. Bianchi Porro G, Lazzaroni M, Imbresi V, et al. 2000. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inﬂammatory drugs: a prospective, placebo-controlled, double blind, parallel-group study. Dig Liver Dis, 32:201–8. Boutet R, Wilcock M, Mackenzie I. 1999. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the isles of Sicily. Aliment Pharmacol Ther, 13:813–17. Brandi G, Biavati B, Calabrese C, et al. 2006. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol, 101:1756–61. Calabrese C, Bortolotti M, Fabbri A, et al. 2005. Reversibility of GERD ultrastructural alterations and relief of symptoms after Omeprazole treatment. Am J Gastroenterol, 100:537–42. Calabrese C, Fabbri A, Areni A, et al. 2005. Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy. WJG, 11:7657–60. Cheer SM, Prakash A, Faulds D, et al. 2003. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs, 63:101–33. Chen TJ, Chou LF, Hwang SJ. 2003. Trends in prescribing proton pump inhibitors in Taiwan: 1. Int J Clin Pharmacol Ther, 41:207–12. Collen MJ, Abdulian JD, Chen YK. 1995. Gastroesophageal reﬂux disease in the elderly: more severe disease that requires aggressive therapy. Am J Gastroenterol, 90:1053–7. Dent J, Brun J, Fendrick AM, et al. 1999. An evidence-based appraisal of reﬂux disease management. The Genval Workshop Report. Gut, 44(suppl 2):S1–S16. Devault KR. 2006. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther, 23(suppl 1):33–9. Dimenas E, Carlsson G, Glise H, et al. 1996. Relevance of normal values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl, 221:8–13. Donnellan C, Sharma N, Preston C, et al. 2005. Medical treatments for the maintenance therapy of reﬂux esophagitis and endoscopic negative reﬂux disease. Cochrane Database Syst Rev, CD003245. Dupas JL, Houche PH, Giret d’Orsay G, et al. 1998. Pantoprazole versus lansoprazole in patients with reﬂux esophagitis. Meta-analysis of two French studies. Digestion, 59(suppl 2):A604. Earnest DL, Robinson M. 1999. Treatment advances in acid secretory disorders: The promise of rapid symptom relief with disease resolution. Am J Gastroenterol, 94(suppl):S18–S24. el-Serag HB, Sonnenberg A. 1997. Associations between different forms of gastro-esophageal reﬂux disease. Gut, 41:594–9. Escourrou J, Deprez P, Saggioro A, et al. 1999. Maintenance therapy with pantoprazole 20 mg prevents relapse of reﬂux oesophagitis. Aliment Pharmacol Ther, 13:1481–92. Fitton A, Wiseman L. 1996. Pantoprazole: a review of its pharmacologic properties and therapeutic use in acid related disorders. Drugs, 51:460–82. Freston JW. 1997. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol, 92: S51–S57. Garnett WR. 1998. Considerations for long-term use of proton pump inhibitors. Am J Health Syst Pharm, 55:2268–79. Clinical Interventions in Aging 2007:2(1) Management of GERD in the elderly with pantoprazole Goudie BM, McKenzie PE, Cipriano J, et al. 1996. Repeat prescribing of ulcer healing drugs in general practice-prevalence and underlying diagnosis. Aliment Pharmacol Ther, 10:147–50. Hetzel DJ, Dent J, Reed WD, et al. 1998. Healing and relapse of sever peptic esophagitis after treatment with omeprazole. Gastroeneterology, 95:903–12. Hungin AP, Rubin G, O’Flanagan H. 1999. Factors inﬂuencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract, 49:463–4. Hungin AP, Rubin GP, O’Flanagan H. 1999. Co-prescription of potentially interacting H2 receptor blockers and proton pump inhibitors with warfarin in general practice. Postgrad Med J, 75:721–2. Hungin AP, Rubin GP, O’Flanagan H. 1999. Long term prescribing of proton pump inhibitors in general practice. Br J Gen Pract, 49:451–3. Hurenkamp GJ, Grundmeyer HG, Bindels PJ, et al. 2002. How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices. J Fam Pract, 51:241–5. Jacobson BC, Ferris TG, Shea TL, et al. 2003. Who is using chronic acid suppression therapy and why? Am J Gastroenterol, 98:51–8. Jalving M, Koornstra JJ, Wesseling J, et al. 2006. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther, 24:1341–48. Johnsson F, Moum B, Vilien M, et al. 2002. On-demand treatment in patients with oesophagitis and reﬂux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol, 37:642–7. Kaplan-Machlis B, Spiegler GE, Revicki DA. 1999. Health-related quality of life in primary carepatients with gastroesophageal reﬂux disease. Ann Pharmacother, 33:1032–6. Kaspari S, Kupcinskas L, Heinze H, et al. 2005. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reﬂux disease. Eur J Gastroenterol Hepatol, 17:935–41. Katz PO. 1999. Treatment of gastroesophageal reﬂux disease: use of algorithms to aid in management. Am J Gastroenterol, 94(suppl): S3–S10. Kovacs T, Wilcox CM, Devault K, et al. 2002. Pantoprazole US GERD Study Group B: comparison of efﬁcacy pf Pantoprazole vs nizatidine in the treatment of erosive esophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther, 16:2043–52. Laine L, Ahnen D, McClain C, et al. 2000. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther, 14:651–68. Lassen A, Hallas J, Schaffalitzky De Muckadell OB. 2004. Use of anti- secretory medication: a population-based cohort study. Aliment Pharmacol Ther, 20:577–83. Lieberman D. 1987. Medical therapy for chronic reﬂux esophagitis. Long term follow up. Arch Int Med, 147:1717–20. Maekava T, Kinoshita Y, Okada A, et al. 1998. Relationship between severity and symptoms of reﬂux esophagitis in the elderly patients in Japan. J Gastroenterol Hepatol, 13:927–30. Majumdar SR, Soumerai SB, Farraye FA, et al. 2003. Chronic acid-related disorders are common and under investigated. Am J Gastroenterol, 98:2409–14. Mold JV, Reed LE, Davis AB, et al. 1991. Prevalence of gastroesophageal reﬂux in elderly patients in a primary care setting. Am J Gastroenterol, 86:965–70. Monnikes H, Pfaffenberger B, Gatz G, et al. 2005. Novel measurement of rapid treatment success with ReQuest: ﬁrst and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg Pantoprazole or 20 mg Esomeprazole. Digestion, 71:152–8. Moosner J, Koop H, Porst H, et al. 1997. One-year prophylactic efﬁcacy and safety of pantoprazole in controlling gastro-oesophageal reﬂux patients with healed reﬂux oesophagitis. Aliment Pharmacol Ther, 11:1087–92. 91